1. Home
  2. HSDT vs XGN Comparison

HSDT vs XGN Comparison

Compare HSDT & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Helius Medical Technologies Inc. (DE)

HSDT

Helius Medical Technologies Inc. (DE)

HOLD

Current Price

$1.77

Market Cap

95.2M

Sector

Health Care

ML Signal

HOLD

Logo Exagen Inc.

XGN

Exagen Inc.

HOLD

Current Price

$6.63

Market Cap

110.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HSDT
XGN
Founded
N/A
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.2M
110.7M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
HSDT
XGN
Price
$1.77
$6.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
7
Target Price
$4.00
$8.86
AVG Volume (30 Days)
100.0K
388.0K
Earning Date
05-19-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
57.27
N/A
EPS
N/A
N/A
Revenue
$6,017,000.00
N/A
Revenue This Year
$91.56
$8.12
Revenue Next Year
N/A
$13.00
P/E Ratio
N/A
N/A
Revenue Growth
1057.12
N/A
52 Week Low
$1.19
$2.59
52 Week High
$25.50
$12.23

Technical Indicators

Market Signals
Indicator
HSDT
XGN
Relative Strength Index (RSI) 55.63 67.07
Support Level $1.60 $2.90
Resistance Level $1.82 $6.93
Average True Range (ATR) 0.07 0.43
MACD 0.01 0.15
Stochastic Oscillator 97.06 81.40

Price Performance

Historical Comparison
HSDT
XGN

About HSDT Helius Medical Technologies Inc. (DE)

Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities.

About XGN Exagen Inc.

Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.

Share on Social Networks: